viewShield Therapeutics PLC

Shield Therapeutics confident of securing a US deal this year as profits return

The profit followed an US$11.4mln upfront payment from ASK Pharm, the group's partner in China

Shield Therapeutics PLC -
Revenues for the half-year to June jumped to £8.9mln (2019:£430,000)

Shield Therapeutics PLC (LON:STX), the iron deficiency treatment specialist swung strongly into profit in its first half following an US$11.4mln upfront payment from ASK Pharm, its partner in China.

Revenues for the half-year to June 30, 2020, jumped to £8.9mln (2019: £430,000) with net sales in Europe of Feraccru, its flagship product, rising by 50%.

Shield posted a profit for the six month period of £3.1mln against a loss of £4.2mln over the same period a year ago, while there was a cash inflow of £2mln that has boosted the total balance to £6.5mln.

in the results statement, Tim Watts, Shield's chief executive said it was making ‘excellent’ progress in China with ASK in reaching agreement on a development plan for Feraccru with the regulatory authorities.

In Europe, Watts said sales of Feraccru in the first half matched the whole of 2019 even with disruption from the coronavirus pandemic.

Shield’s priority for the rest of the year is to find a US partner, he added.

Feraccru is known as Accrufer in the US and Watts said the company has been engaging with possible partners in a broad range of iron deficiency therapy areas.

“Several of these have signed confidentiality agreements, several have submitted non-binding offers and more detailed negotiations have been undertaken with a number of parties,” he noted.

“ We remain confident of securing a partner in 2020 and have recently ordered launch stocks of US packs of Accrufer which should be available for sale by around the end of 2020.”

Quick facts: Shield Therapeutics PLC


Price: 40.75 GBX

Market Cap: £87.97 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Shield Therapeutics' on cusp of US market expansion with focus on...

Shield Therapeutics PLC (LSE:STX, FRA:1JS)'s (LON:STX, OTCQX:SHIEF) investment case is presented by Proactive Research Analyst John Savin who explains how the firm hinges on the success of their US launch of commercialising Accrufer. This treatment is for iron deficiency or anaemia and as...

3 weeks, 3 days ago

2 min read